A Review on Evolution of Medicine After and During Corona

Year : 2024 | Volume :14 | Issue : 01 | Page : 1-9
By

Bhagyashri N. Patil

Bhupendra A. Patil

Amruta N. Patil

Sunil P. Pawar

  1. Student P.S.G.V.P. Mandal’s Collage of Pharmacy Maharashtra India
  2. Student P.S.G.V.P. Mandal’s Collage of Pharmacy Maharashtra India
  3. Assistant Professor P.S.G.V.P. Mandal’s Collage of Pharmacy Maharashtra India
  4. Principal P.S.G.V.P. Mandal’s Collage of Pharmacy Maharashtra India

Abstract

As of the beginning of 2023, 6.7 million people had perished from COVID-19, according to the World Health Organization. However, there have also been some positive developments, such as the notable decline in influenza-related deaths in the first year of the pandemic as a result of masking and social isolation, as well as the quick adoption of vaccines utilizing cutting-edge technologies like mRNA vaccines, which hold out great promise for combating other infectious diseases. The necessity of interdisciplinary approaches for tackling complicated problems is one lesson to be learned from the pandemic. With only virology, we are unable to contain a viral epidemic. To understand the relationships between human behavior, disease transmission, government interventions, global transport and trade, and the production and distribution of vaccines and treatments, among others, we need epidemiologists, engineers, sociologists, political scientists, historians, medical doctors, economists, statisticians, anthropologists, mathematicians, and geographers. The global COVID-19 pandemic has caused a shift in the priority of medical and surgical operations. Numerous healthcare systems have ceased doing their regular screenings as a result of it. The reference rate was significantly lower—especially among the elderly—after medical clinics were converted to COVID-19 referral facilities, lockdowns were implemented, and the public was afraid to refer patients to medical centers. The development of medicine both during and after the Corona is highlighted in this review essay.

Keywords: COVID-19, Pandemic, SARS-CoV-2, Coronavirus, Treatment, Therapy.

[This article belongs to Research & Reviews: A Journal of Pharmacology(rrjop)]

How to cite this article: Bhagyashri N. Patil, Bhupendra A. Patil, Amruta N. Patil, Sunil P. Pawar. A Review on Evolution of Medicine After and During Corona. Research & Reviews: A Journal of Pharmacology. 2024; 14(01):1-9.
How to cite this URL: Bhagyashri N. Patil, Bhupendra A. Patil, Amruta N. Patil, Sunil P. Pawar. A Review on Evolution of Medicine After and During Corona. Research & Reviews: A Journal of Pharmacology. 2024; 14(01):1-9. Available from: https://journals.stmjournals.com/rrjop/article=2024/view=143315





Browse Figures

References

1. Sunstein, Cass R. “Sludge audits.” Behavioural Public Policy 6.4 (2022): 654-673.
2. Centers for Medicare & Medicaid Services. Medicare telemedicine health care provider fact sheet. 2020. https://www.cms.gov/newsroom/fact-sheets/medicare-telemedicine-health-careprovider-fact-sheet. Cited 6 April 2021.
3. Wang Chen, Horby Peter W, Hayden Frederick G, Gao George F. A novel coronavirus outbreak of global Health concern. The Lancet. 2020; 395(10223):470–473. Doi: 10.1016/S0140- 6736(20)30185-9.
4. Reimers FM. Learning from a pandemic: the impact of COVID-19 on education around the world. In: Primary and Secondary Education During COVID-19. Cham: Springer, 2022, 1–37 https://doi.org/10.1007/978-3-030-81500-4_1 .
5. Removing regulatory barriers to Telehealth before and after COVID-19Nicol Turner Lee, Jack Karsten, and Jordan Roberts 2020, Brookings. https://www.brookings.edu/articles/removing-regulatory-barriers-to-telehealth-before-and-after-covid-19/
6. Bhattacharjee, B.; Acharya, T. The COVID-19 Pandemic and its Effect on Mental Health in USA—A Review with Some Coping Strategies. Psychiatr. Q. 2020, 91(4), 1135–1145 doi: 10.1007/s11126-020-09836-0.
7. Arora P, Mehta D, Ha J. Impact of telehealth on health care resource utilization during the COVID-19 pandemic. J Comp Eff Res. 2022 Apr;11(5):301-309. doi: 10.2217/cer-2021-0242.
8. Mann DM, Chen J, Chunara R, Testa PA, Nov O. COVID-19 transforms health care through telemedicine: Evidence from the field. J Am Med Inform Assoc. 2020 Jul 1;27(7):1132-1135. doi: 10.1093/jamia/ocaa072.
9. Doraiswamy S, Abraham A, Mamtani R, Cheema S. Use of Telehealth During the COVID-19 Pandemic: Scoping Review. J Med Internet Res. 2020 Dec 1;22(12):e24087. doi: 10.2196/24087.
10. Bitar H, Alismail S. The role of eHealth, telehealth, and telemedicine for chronic disease patients during COVID-19 pandemic: A rapid systematic review. Digit Health. 2021 Apr 19;7:20552076211009396. doi: 10.1177/20552076211009396.
11. Weinstein RS, Lopez AM, Joseph BA, Erps KA, Holcomb M, Barker GP, Krupinski EA. Telemedicine, telehealth, and mobile health applications that work: opportunities and barriers. Am J Med. 2014 Mar;127(3):183-7. doi: 10.1016/j.amjmed.2013.09.032.
12. Humphreys J, Schoenherr L, Elia G, Saks NT, Brown C, Barbour S, Pantilat SZ. Rapid Implementation of Inpatient Telepalliative Medicine Consultations During COVID-19 Pandemic. J Pain Symptom Manage. 2020 Jul;60(1):e54-e59. doi: 10.1016/j.jpainsymman.2020.04.001.
13. Monique Mrazek & Ruchira Shukla,2020,After coronavirus, telemedicine is here to stay,World Bank Blogs, https://blogs.worldbank.org/digital-development/after-coronavirus-telemedicine-here-stay.
14. Andrew perrin and Sara atske,7% of Americans don’t use the internet. Who are they?, Pew Research Center,2021, Available from: https://www.pewresearch.org/short-reads/2021/04/02/7-of-americans-dont-use-the-internet-who-are-they/
15. Pavia C.S., Gurtler V. Elsevier, Academic Press; London, UK: 2020. Methods in microbiology Volume 47. Immunological Methods in Microbiology; pp. 1–394.
16. BERSON SA, YALOW RS. Quantitative aspects of the reaction between insulin and insulin-binding antibody. J Clin Invest. 1959 Nov;38(11):1996-2016. doi: 10.1172/JCI103979.
17. YALOW RS, BERSON SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 1960 Jul;39(7):1157-75. doi: 10.1172/JCI104130.
18. Centers for Disease Control and Prevention, Overview of Testing for SARS-CoV-2, the virus that causes COVID-19, 4 September 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html
19. World Health Organization Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing 2022, https://www.who.int/publications/i/item/WHO-2019-nCoV-Ag-RDTs-Self_testing-2022.1
20. S Pavia C, M Plummer M. The evolution of rapid antigen detection systems and their application for COVID-19 and other serious respiratory infectious diseases. J Microbiol Immunol Infect. 2021 Oct;54(5):776-786. doi: 10.1016/j.jmii.2021.06.003
21. Coronavirus (COVID-19) Update: FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients Statement From: Stephen M. Hahn, M.D.Commissioner of Food and Drugs – Food and Drug Administration ( December 2019 – January 2021 )Jeffrey E. Shuren, MD, JDDirector – CDRH Offices: Office of the Center Director
22. Cyranoski D. Alarming COVID variants show vital role of genomic surveillance. Nature. 2021 Jan;589(7842):337-338. doi: 10.1038/d41586-021-00065-4.
23. Saravanan KA, Panigrahi M, Kumar H, Rajawat D, Nayak SS, Bhushan B, Dutt T. Role of genomics in combating COVID-19 pandemic. Gene. 2022 May 20;823:146387. doi: 10.1016/j.gene.2022.146387
24. INSACOG Indian Sars-Cov-2 Genomics Consortium, https://dbtindia.gov.in/insacog
25. Oishi SM, Marshall N, Hamilton AB, Yano EM, Lerner B, Scheuner MT. Assessing multilevel determinants of adoption and implementation of genomic medicine: an organizational mixed-methods approach. Genet Med. 2015 Nov;17(11):919-26. doi: 10.1038/gim.2015.7.
26. Hoffmann, M.; Monaghan, M.T.; Reinert, K. PriSeT: Efficient de novo primer discovery. In Proceedings of the 12th ACMConference on Bioinformatics, Computational Biology, and Health Informatics, Gaineswille, FL, USA, 1–4 August 2021; pp. 1–12.
27. Mohammadi M, Meskini M, do Nascimento Pinto AL. 2019 Novel coronavirus (COVID-19) overview. Z Gesundh Wiss. 2022;30(1):167-175. doi: 10.1007/s10389-020-01258-3.
28. Sherif B, Hafez HM, Abdelhalim MR, Elwafa MAZA, Wahba NS, Hamdy P. Evaluation of diagnostic performance of SARS-CoV-2 detection kits: a comparative study. Beni Suef Univ J Basic Appl Sci. 2023;12(1):17. doi: 10.1186/s43088-023-00360-1.
29. Pranav singh Dhunnoo, The Evolution Of COVID-19 Rapid Tests Paves The Way For At-Home Lab Tests, The Medical Futurist,2020, https://medicalfuturist.com/the-evolution-of-covid-19-rapid-tests-paves-the-way-for-at-home-lab-tests/
30. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436.
31. Jessica McDonald,Q & A On Paxlovid, Pfizer’s COVID-19 Oral Antiviral,FactCheck.org, https://www.factcheck.org/2022/05/scicheck-qa-on-paxlovid-pfizers-covid-19-oral-antiviral/
32. Bayer V. An Overview of Monoclonal Antibodies. Semin Oncol Nurs. 2019 Oct;35(5):150927. doi: 10.1016/j.soncn.2019.08.006.
33. Shepard HM, Phillips GL, D Thanos C, Feldmann M. Developments in therapy with monoclonal antibodies and related proteins. Clin Med (Lond). 2017 Jun;17(3):220-232. doi: 10.7861/clinmedicine.17-3-220.
34. Keam SJ. Tixagevimab + Cilgavimab: First Approval. Drugs. 2022 Jun;82(9):1001-1010. doi: 10.1007/s40265-022-01731-1.
35. Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Near KA, Padilla KW, Psachoulia K, Sharbaugh A, Streicher K, Pangalos MN, Esser MT; PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022 Jun 9;386(23):2188-2200. doi: 10.1056/NEJMoa2116620.
36. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID- 19 in the New York City Area [published correction appears in doi:10.1001/jama.2020.7681]. JAMA. 2020;323(20):2052–2059
37. Mechanical Ventilation Committee of the Brazilian Intensive Care Medicine Association Commission of Intensive Therapy of the Brazilian Thoracic Society Brazilian recommendations of mechanical Ventilation 2013 Part I. J Bras Pneumol. 2014;40(4):327–363. Doi:10.1590/S1806- 37132014000400002
38. Dunne EM, Balletto BL, Donahue ML, Feulner MM, DeCosta J, Cruess DG, et al. The benefits of yoga for people living with HIV/AIDS: A systematic review and meta-analysis. Complement Ther Clin Pract. 2019;34:157–64.
39. Goyal M. Potential of Ayurveda in the prevention and management of post-COVID complications. Ayu. 2020 Apr-Jun;41(2):69-71. doi: 10.4103/ayu.ayu_284_21.


Regular Issue Subscription Review Article
Volume 14
Issue 01
Received February 20, 2024
Accepted March 15, 2024
Published March 28, 2024